Previous Close | 0.1230 |
Open | 0.1300 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.1198 - 0.1391 |
52 Week Range | 0.0930 - 0.5560 |
Volume | |
Avg. Volume | 121,503 |
Market Cap | 16.516M |
Beta (5Y Monthly) | 1.59 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0900 |
Earnings Date | Jun 28, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
BEVERLY, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated, multiplexing PCR-based syndromic testing in veterinary clinics, is pleased to announce that it has entered into a purchase agreement with a veterinary hospital in Wisconsin. Dr. Jack Regan, LexaGene’s CEO and Founder stated, “We are pleased to announce this sale to a veterinar
BEVERLY, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”) announces, further to its news release on June 28, 2022, the Company has been granted a management cease trade order (“MCTO”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”) imposed against certain insiders of the Company, precluding them from trading securities of the Company. The MCTO will be in effect until the Company’s annual financia
BEVERLY, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”) announces that it has filed an initial registration statement with the United States Securities and Exchange Commission (the “SEC”) on Form 10 under the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”), which includes audited financial statements prepared in accordance with United States generally accepted accounting principles (“U.S. GAA